Cartesian Therapeutics, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $6.12
- 52-Week Range
- $5.60 – $11.00
- Market Cap
- $192.17M
- P/E (TTM)
- —
- EPS (TTM)
- -4.78
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -19.23%
- Gross Margin
- 0.00%
- Operating Margin
- -10009.17%
- Profit Margin
- 0.00%
- Current Ratio
- 8.38
- Debt/Equity
- —
- Total Debt
- $60.34M
- Free Cash Flow
- $-58.12M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $129.53M
Market Snapshot
About
Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel cell therapies for autoimmune diseases. The company utilizes its proprietary RNA chimeric antigen receptor (RNA CAR) technology to create off-the-shelf cellular immunotherapies. Cartesian is focused on B cell-mediated autoimmune conditions with significant unmet medical needs.